Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Tonix Pharmaceuticals Holding Corp Common Stock (TNXP).
- Disclosed ownership: 6.4%.
- Date of event: 30 Sep 2025.
VANGUARD GROUP INC - 30 Sep 2025 SCHEDULE 13G Report for Tonix Pharmaceuticals Holding Corp Common Stock (TNXP)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Symbol
- TNXP
- Shares outstanding
- 8,770,976 shares
- Disclosed Ownership
- 556,957 shares
- Ownership
- 6.4%
- Form type
- SCHEDULE 13G
- Filing time
- 31 Oct 2025, 11:31:40 UTC
- Date of event
- 30 Sep 2025
- Next filing
- 30 Jan 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 6.4% ownership in Tonix Pharmaceuticals Holding Corp Common Stock (TNXP) on 30 Sep 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 31 Oct 2025, 11:31.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 6.4% | 556,957 | 0 | 57,410 | Ashley Grim | Head of Global Fund Administration |